Emcure – Indian Oncology Medicines
Emcure
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981 by Satish Mehta and headquartered in Pune, Maharashtra. Since July 2024 its shares have been listed on India's NSE and BSE stock exchanges.
Emcure makes oral and injectable medicines as well as biotech products. Its main areas are gynaecology, cardiology, oncology and haematology, and treatments for HIV and other infections. The company has a long record in antiretroviral therapy: in 2006 it signed licensing agreements with Bristol-Myers Squibb for atazanavir and with Gilead for tenofovir.
The Emcure group includes the biotech company Gennova Biopharmaceuticals. In 2022 its mRNA COVID-19 vaccine, GEMCOVAC-19, received emergency use authorisation in India, becoming the first mRNA vaccine developed in the country.
The company's manufacturing sites are in India. According to Emcure, its products reach more than 70 countries; in Europe and Canada it operates through its subsidiaries Tillomed Laboratories (UK) and Marcan Pharmaceuticals.
Unifarm carries Emcure's HIV and oncology medicines: Viropil (tenofovir, lamivudine and dolutegravir), Instgra (dolutegravir), Megval (melphalan) and Ematra (tretinoin).